Westwater Resources

Phase A — Understand the business

Lens 1 · Company Overview

Westwater Resources is a Delaware-incorporated, Centennial-CO-headquartered "energy technology" company (originally Uranium Resources, Inc., incorporated 1977; renamed and pivoted to graphite in August 2017) pursuing a vertically integrated "mine-to-market" battery-grade natural-graphite strategy anchored by two Coosa County, Alabama assets:

• Kellyton Graphite Plant — a planned battery-grade graphite processing facility. Under construction since Q4 2021. Phase I targets ~26,500 mt/yr total product (12,500 mt ULTRA-CSPG™ coated spherical purified graphite + 14,000 mt SG Fines); Phase I+II would scale to ~106,000 mt/yr. CSPG is the active anode material (AAM) in lithium-ion batteries.
• Coosa Graphite Deposit — an exploration-stage flake-graphite deposit (mineral resources, no reserves) on ~41,965 leased acres; intended as future feedstock. Also contains vanadium (untested optionality).

Business model in plain terms: buy flake-graphite concentrate from a third party (Syrah Resources, contracted to ≥2028, plus a non-FEOC backup supplier), process it at Kellyton into purified coated spherical graphite via a patented non-hydrofluoric-acid purification process (first U.S. patent issued Sept 17, 2025; >99.95% carbon purity), and sell CSPG/AAM to battery makers and OEMs. The pitch is a domestic, non-FEOC ("Foreign Entity of Concern") anode source for U.S./allied supply chains.

Contract structure / customers — the central problem. WWR's two anchor offtakers both terminated in a five-month window:

• FCA (Stellantis) binding offtake (signed Jul 17 2024) — terminated Nov 3 2025.
• SK On Products Procurement Agreement (signed Feb 4 2024) — terminated Mar 31 2026.
• The only surviving offtake is Hiller Carbon (fines offtake, Sept 2024) — a low-value by-product stream, not the CSPG prize.

So as of the latest filing the company has zero committed customer for its primary Phase-I product (CSPG). 20 full-time employees (Dec 31 2025); one reportable segment ("battery-grade graphite business").

Lens 2 · Supply Chain (name the names)

Map, upstream → WWR → end market:

• Flake-graphite feedstock (upstream): Syrah Resources Ltd (ASX:SYR) — primary concentrate supplier under a contract WWR says runs to ≥2028; source is Syrah's Balama mine (Mozambique) / Vidalia (LA) chain. A second, unnamed "non-FEOC" backup supplier was added in 2025. Chokepoint: Balama has been on care-and-maintenance amid the graphite price collapse — WWR's "secure feedstock" rests partly on a mine that isn't currently running at capacity.
• The company (midstream): Kellyton processing (sizing → spheroidization → classification → caustic-bake/acid-leach/thermal purification → carbon coating). Single-site, single-line Phase I. Never operated at commercial scale — only a qualification line has run, producing >1 mt of CSPG samples cumulatively.
• Coosa (aspirational upstream): intended in-house feedstock, but exploration-stage, no reserves, permitting only just begun (NPDES filed Feb 26 2026; FAST-41 "covered project" designation; USACE §404 individual permit targeted 2H 2026). Kellyton's own economics explicitly assume third-party feedstock, not Coosa. Coosa is a long-dated option, not a supply-chain link that exists yet.
• End customers (downstream): intended — EV/truck/bus battery makers, BESS (grid + data-center), consumer electronics, defense/aerospace. Actual committed — none for CSPG after the FCA/SK On terminations; Hiller Carbon takes fines. Named prospects cited generically as "large global lithium-ion battery manufacturers and OEMs" — no signed replacement.

Single-source dependencies: feedstock effectively concentrated on Syrah; the entire downstream is a single unbuilt plant; and the demand side has no contracted anchor. This is a chain with a weak link at both ends.

Lens 3 · Competitive Advantages (moats)

Claimed moats, stress-tested:

• Patented purification IP (non-HF). One issued U.S. patent + one pending; genuinely differentiated on ESG/permitting (avoids hydrofluoric acid; claims ~10% lower GHG than Chinese natural-graphite processing, ~44% lower than Chinese synthetic). But a single early-stage patent on an unproven-at-scale process is a thin moat, and the company concedes no member of management has ever produced graphite commercially.
• "Domestic / non-FEOC" positioning. The intended moat — a supply-chain-security premium. This moat's value just collapsed (see Lens 8): the ~160% Chinese-anode tariff that would have monetized "domestic" was struck down by the ITC in March 2026, and both offtakers walked immediately after. Without a tariff wall or an IRA/45X domestic-content mandate that actually bites, domestic anode competes against Chinese product that is ~50–70% cheaper.
• Bargaining power: effectively none. WWR needs its customers (it has none), needs its feedstock supplier, and needs the capital markets far more than any of them need WWR. A pre-revenue micro-cap has zero leverage over a battery OEM or a lender.
• Resource "moat": marketing calls Coosa "65 square miles of one of the richest graphite deposits in the world." The grade says otherwise — Indicated 2.89% Cg, Inferred 3.08% Cg. That is low grade for flake graphite (top deposits run high-single to mid-teens % TGC; Syrah's Balama is ~16%). Low grade + exploration-stage + no reserves = not a moat, an option.

Verdict on moat: narrow and deteriorating. The one real differentiator (non-HF IP) doesn't matter if the plant is never funded and there's no customer.

Lens 4 · Segments

One segment, zero revenue — there is nothing to break out by product or geography. segments.csv on the shelf is header-only (0 rows) because the company reports a single "battery-grade graphite business" segment, entirely pre-revenue, all in Coosa County, Alabama. The only meaningful "segment" split is cost geography: Alabama (project/opex) vs. Corporate. Q1 2026 net loss split: battery-graphite segment $(2.08)M, corporate/other $(2.60)M = $(4.68)M consolidated. Read that twice — more than half of the cash loss is corporate overhead (G&A/stock-comp), not project spend. For a company that has paused construction to conserve cash, the overhead-heavy loss mix is a governance flag (see Lens 9).

---

Phase B — Measure performance (adapted: burn, not earnings)

Lens 5 · "Earnings" Result (the loss & burn print)

There is no revenue and no beat/miss. The relevant print is the loss trajectory and cash burn:

Reads:

• FY2025 loss more than doubled ($12.7M → $27.3M), but the increase is ~$11.4M of non-cash/financing losses on the convertible notes (the Series A-1 note alone booked a $9.9M loss on $5M principal as the stock rose and holders converted) plus +$2.4M higher stock comp. Underlying operating burn is smaller but rising.
• Q1 2026: $41.5M cash after a $7.1M single-quarter drawdown. But that quarter included $2.7M of withholding-tax cash paid on vesting RSUs — i.e., the company paid out more cash to cover employee equity taxes ($2.7M) than it raised from the market ($1.2M ATM) in Q1. Net financing was cash-negative $(1.5)M. That is a striking optic for a company that needs $100M+.
• Balance sheet: $189.1M total assets, of which $144.4M is property/plant/equipment — and $128.2M of that is "construction-in-progress" (a half-built plant). Total liabilities only $10.4M (AP $4.4M + $3.7M convertibles). Book equity $178.7M. No debt of consequence — the entire enterprise has been funded with equity and toxic converts.
• No going-concern qualification. Baker Tilly (auditor since 2017) issued a clean opinion, no critical audit matters. Management asserts cash covers "non-discretionary expenditures beyond a year." Note the load-bearing word "non-discretionary" — the ~$115M to actually finish Phase I is discretionary and entirely unfunded.
• Market reaction: the stock trades at ~$0.47, ~$60M market cap, at its 52-week low ($0.46–$3.75 range) — i.e., ~0.33× book value. The market is pricing the $128M of construction-in-progress at a deep discount because a half-built, un-offtaken, unfinanced plant is worth far less than its sunk cost.

Lens 6 · "Earnings Calls" (sentiment trend)

transcripts/ is empty (0) — WWR is a micro-cap that does not host substantive quarterly analyst calls; there is no sell-side Q&A tape to sentiment-analyze. The management-communication trend is instead visible in the cadence of press releases, which has shifted decisively from commercialization to damage control:

• 2024: signing offtakes (FCA, SK On), "$1.4B NPV" DFS, "lead lender approval" for debt syndication — momentum framing.
• Nov 2025: "Strategic Update" — FCA termination, debt syndication paused, construction slowed to "measured pace" — retrenchment.
• Apr 2026: "Commercial Update" — SK On termination; CEO Bakker: "SK On's decision reflects the challenging and evolving environment our customers are navigating" — explaining away customer losses.
• The recurring new phrase is "measured approach to capital deployment" and "prioritizing non-dilutive... government programs" — the language of a company that has stopped building and is waiting for a bailout. The thing they stopped saying: firm start-up dates and named customers.

Lens 7 · Comps (peer table)

A pre-revenue graphite-developer cohort — none profitable, so P/E, EV/EBIT, dividend yield, ROE are n/a for the entire group by construction, and I will not fabricate them. The meaningful axes are size, funding status, and offtake/anchor quality:

[EV/Sales, EV/EBIT, P/E, div yield, 5yr ROE: n/a / not applicable (pre-revenue cohort).]

The comp takeaway is the whole thesis in one row: WWR is the smallest name in the cohort, the only one with neither a committed government loan nor a live offtake. NOVONIX (a $754.8M DOE loan + blue-chip offtakes) is what a funded domestic-anode player looks like; WWR is not that. The market-cap gap (WWR ~$60M vs. peers $175–500M) is the market pricing exactly that funding/anchor deficit.

Lens 8 · Stock-Price Catalysts (what actually moves WWR)

WWR is a policy-and-financing-headline stock, not a fundamentals stock (there are no fundamentals yet). The 5-year tape shows violent, catalyst-driven swings; 2025 alone ranged $0.46 → $3.48. The pattern:

• Up-catalysts (historical): critical-minerals executive orders, tariff-investigation initiations, offtake signings, capital raises framed as "strategic," Benchmark/IEA demand headlines, and the 2025 run-up on anticipation of the Chinese-anode AD/CVD tariff.
• THE catalyst that broke — the tariff (decisive): On Feb 11 2026, DOC issued final affirmative AD (93.5%) + CVD (66.68%) determinations on Chinese active anode material — a ~160% combined duty wall. This was the entire "domestic anode gets competitive" thesis. Then on Mar 12 2026, the USITC voted negative (2–1) on injury — finding Chinese AAM imports do not materially retard establishment of a U.S. industry — which means Commerce will NOT issue the AD/CVD orders. No duties.. The single biggest structural tailwind was killed at the finish line.
• The customer dominoes followed the policy: SK On terminated Mar 31 2026 — 19 days after the ITC vote. FCA had gone in Nov 2025. The stock round-tripped its entire 2025 rally back to the $0.46 low.
• What this reveals: WWR's equity is a levered call option on U.S. critical-minerals policy (tariffs, EXIM/DOE loans, DPA/45X). It reacts to Washington, not to Kellyton throughput. That cuts both ways — see the short-squeeze warning in Lens 13.

---

Phase C — Judge people & books

Lens 9 · Management

• Frank Bakker — President & CEO (since Jan 16 2023). Career is industrial plant operations/construction — DSM (NL), OCI Partners (ammonia/methanol), US Methanol LLC (CEO), BD Energy, Altivia; ME degree + MBA. Fit: genuinely relevant to building and commissioning a chemical plant (Kellyton is essentially a specialty-chemical facility). Gap: no graphite/battery-materials, mining, or capital-markets pedigree — and the filing itself concedes management has never produced graphite commercially. He is a plant-builder inheriting a financing and commercial crisis, not a dealmaker who can conjure an offtake or a government loan.
• Terence J. Cryan — Executive Chairman (Exec Chairman since Feb 26 2022; on/around the board since 2006; interim CEO 2012–13). Background is energy investment banking / private equity. He is the capital-markets architect — and his long tenure spans the entire Uranium-Resources→Westwater pivot and the serial dilution. Skin-in-the-game is the question: insider ownership is not large (the shelf's insider-transactions.csv is absent), and the board is only five directors, three independent.
• Capital-allocation history — the damning line. Since the 2017 graphite pivot the company has raised and spent ~$130M on a plant that still can't run, run an accumulated deficit to $405.7M, and diluted shares from ~55M (Jan 2024) to ~127M (May 2026) — ~2.3× in 28 months. It funded 2025 partly with floating-price convertible notes (Lens 10) — among the most shareholder-unfriendly instruments available. This is value destruction on the capital-allocation scorecard, however sympathetic the macro.
• Comp/overhead flag: in Q1 2026 the corporate/G&A loss ($2.6M) exceeded the actual project loss ($2.1M), and the company paid $2.7M cash in RSU withholding taxes while construction was paused. Stock comp jumped on "larger, more broadly distributed RSU awards granted May 2025." Rewarding the team with equity while shareholders are diluted 2.3× and the stock sits at all-time-adjusted lows is a governance smell.
• Archetype: professional managers running a survival-and-await-policy playbook, not founder-operators with conviction capital at risk.

Lens 10 · Forensic Red Flags

Forensic lens — every figure labeled.

• Floating-price ("death-spiral"-style) convertible notes — the biggest flag. The Series A-1 ($5M, Jun 2025) and Series B-1 ($5M, Aug 2025) notes convert at fixed prices ($0.63 / $0.83) OR, on monthly installment conversions, at the lower of that price or 92% of the lowest VWAP over the prior 5 trading days. That structure means a falling stock mints more shares — reflexive dilution. They carry an 18% default rate, a $2.25M minimum-cash covenant, a 9.99% beneficial-ownership cap, and mature 24 months out (Jun/Aug 2027). The company elected fair-value option accounting, so mark-to-market runs through P&L (the $9.9M FY2025 Series A-1 loss). Remaining principal was down to ~$3.1M by Mar 2026 as the company converted them into ~5.4M shares — the dilution is the repayment. Implied volatility in the FV model: ~99–104%. A funded, credible developer does not need instruments like this; reaching for them is itself a distress signal.
• Serial ATM + ELOC dilution. ~$70.6M ATM capacity (H.C. Wainwright) + ~$26.2M Lincoln Park equity-line remaining as of Mar 2026. The financing model is continuous share issuance. ~19.9M potentially dilutive shares (RSUs + options + converts) overhang the 124.7M base.
• Construction-in-progress impairment risk. $128.2M of CIP sits un-impaired. Management explicitly warns that "if the Company is required to abandon construction... the Company could be required to evaluate recoverability". With both offtakers gone and financing unsecured, an impairment trigger is a live, quarter-to-quarter risk. The clean "no impairment" conclusion depends on management's assumption that Phase I still gets funded — an assumption the market (0.33× book) rejects.
• Reserve/resource optics. Coosa IA "positive economics" (pre-tax NPV@8% $229.2M) rests 89% on Inferred resources — the lowest-confidence category — and the filing states a standalone Indicated-only case is not economic. The economic story leans on the most speculative tonnage. No mineral reserves exist.
• Deferred-cost write-offs tied to lost deals: Q1 2026 booked a $0.1M write-off of deferred contract costs and $0.1M commission expense from the SK On termination, plus the prior write-off of deferred debt-issuance costs when the FCA-anchored syndication was paused. Small in dollars, but they corroborate the commercial unravelling.

Regulatory findings (required sub-section).

• SEC Litigation Releases / AAERs: None. Verified via SEC EDGAR EFTS (LR + AAER) search 2021-07-10→2026-07-10, total_sec_findings: 0.
• 10-K Item 3 (Legal Proceedings): "None.". Q1 10-Q commitments/contingencies note: no material legal accruals expected.
• Non-SEC enforcement (FTC/DOJ/FDA/EPA/etc.): web search surfaced no enforcement actions, consent decrees, fines, or penalties against Westwater Resources. The company's regulatory exposure is permitting (NPDES, USACE §404, ADEM air, ADOL mining), not enforcement.
• Conclusion: No material regulatory or legal findings — verified via SEC EDGAR EFTS (LR, AAER), web search, and 10-K Item 3 as of 2026-07-10. WWR's risk is financial/commercial, not legal/forensic-fraud. (The convertible structure is legal, disclosed, and shareholder-unfriendly — a governance flag, not a compliance violation.)

---

Phase D — Project & stress-test

Lens 11 · Forward Projection (pre-revenue framing — no EPS model; per instruction, no forecast.ts logged)

There is no bottom-up EPS to build — revenue is zero until ~12 months after Phase-I financing closes, and financing has not started. So the projection is a funding/dilution path plus the prize sketch:

• EPS path (base/bull/bear): negative in every case across the next three fiscal years (FY26–FY28). The variable isn't profit — it's how much dilution it takes to survive and (maybe) build.
• Bear (most likely near-term): no offtake, no government loan. Company runs the ATM/converts to fund ~$16–20M/yr non-discretionary burn; construction stays paused; share count grinds from ~127M toward 150M+; stock drifts toward/through the $0.46 low; NYSE American low-price / reverse-split risk (WWR already did a 1-for-50 reverse split in April 2019 for Nasdaq compliance ). CIP impairment becomes a live question. EPS ~$(0.15)–$(0.25).
• Base: EXIM/DOE process advances slowly; a partial offtake or a strategic (à la Eni→NMG) appears; a raise at depressed prices funds a first tranche. Survival with heavy dilution; no production in the window. EPS ~$(0.10)–$(0.20).
• Bull: a government loan (EXIM "Make More in America" / a DOE-style facility) plus a real replacement offtake lands; Phase-I financing closes; production ~12 months later. This is the binary that re-rates the stock multiples — but it requires two hard things to both happen, and the debt itself needs the offtake (Catch-22, below).
• Runway check (the question that matters for a developer): Operating runway — yes: $41.5M cash ÷ ~$4M/quarter paused-construction burn ≈ ~2+ years of survival (consistent with management's "non-discretionary beyond a year"). Construction runway — no: finishing Phase I needs ~$115M (of $245M budget; ~$130M incurred; ~$19M is contingency). Cash covers ~36% of the gap. (A secondary source floated a smaller ~$50M near-term figure; the filing's ~$115M total-remaining is authoritative — flagged conflict.)
• The prize, sketched (illustration only, heavily caveated ``): Phase-I nameplate 12,500 mt CSPG. At an assumed $8,000/t battery-grade CSPG (mid-cycle; spot is depressed 50–70% off 2022 peak, so this is a recovery price) → ~$100M/yr gross Phase-I CSPG revenue. Even a healthy 30–40% EBITDA margin implies ~$30–40M/yr — against $245M of Phase-I capex and a $60M market cap. The prize is real if and only if the plant is funded, built, qualified, sold-out, and graphite prices recover — four sequential conditional gates.
• Project NPV optionality (company-sourced): Kellyton Phase I+II DFS reportedly showed a ~$1.4B NPV; Coosa mine IA after-tax NPV@8% $190.2M / 24.2% IRR. Both are study-stage, pre-financing, and assume commodity prices well above spot. Treat as optionality, not value.
• Per instruction (unattended watchlist), no forecast.ts create logged. If promoted, the scoreable binary is not an EPS line but: "WWR secures a committed project-financing package (government loan and/or ≥$50M debt) AND a new binding CSPG offtake before 2026-12-31" — set p ≈ 0.20.

Lens 12 · Bull vs Bear

Bull case (the steelman). The U.S. is ~100% import-reliant on battery-grade graphite; China controls ~76% of flake output and ~90% of anode processing. Policy wants a domestic anode industry (executive orders, DPA, EXIM, 45X). WWR owns a ~90%-built, permitted-to-complete Phase-I plant with patented non-HF purification and a large (if low-grade) domestic resource — assets that cost $130M and trade for a $60M enterprise. A single catalyst — an EXIM/DOE loan + one blue-chip offtake (the NMG-Eni or NOVONIX-DOE template) — could re-rate it multiples higher off a $0.47 base. Optionality is convex: tiny downside in dollars, large upside on a policy/deal surprise. Cash covers survival for ~2 years, buying time for the tariff/policy pendulum to swing back.

Bear case (2–3 permanent-impairment risks).

1. The commercial anchor is gone and the reason it's gone is structural. Both offtakers walked because domestic anode isn't cost-competitive without a tariff wall, and the ITC killed the tariff wall in March 2026. This isn't a timing problem; it's the market telling WWR its product is uneconomic at current graphite prices. New offtakes require either a price recovery or a policy reversal — neither in WWR's control.
2. The financing Catch-22. Debt (EXIM/lenders) requires offtake to underwrite repayment; offtake requires a funded, credible plant; the plant requires the debt. The FCA termination already collapsed the debt syndication. This loop is not resolvable by management effort alone.
3. Dilution/insolvency spiral. With no revenue and floating-price converts + a permanent ATM, the equity is the ATM. Share count 2.3× in 28 months and rising; reverse-split/listing risk at $0.47; CIP impairment risk if abandonment is contemplated. Existing holders can be right on the macro and still be diluted to nothing before the payoff.

Pre-mortem (18 months out, thesis broke): It's early 2028. No government loan closed (EXIM stalled on the missing offtake; a government shutdown delayed diligence). Graphite stayed cheap; no OEM signed. WWR ran the ATM and converts to ~180M+ shares, did a reverse split to hold the listing, wrote down part of the CIP, and Kellyton is still not producing. The stock is an $0.08-equivalent pre-split shell awaiting a strategic buyer for the assets at cents on the sunk dollar.

Are multiples too high? There are no earnings multiples. On price-to-book the stock is cheap (0.33×) — but that book is 74% a half-built, un-offtaken plant whose recoverable value is unknowable. Cheap-to-book is not cheap if the book impairs.

Contrarian view (what the market may be missing, both ways): The bear consensus is "dead money / zero." The contrarian upside is that critical-minerals policy is bipartisan and escalating, the ITC vote was a 2–1 squeaker that could reverse on appeal or a re-filed case, and Washington has shown it will directly fund domestic anode (NOVONIX's $754.8M DOE loan is the proof). One award turns this $60M option into a multi-bagger. The contrarian downside the bulls miss: even with a loan, WWR still has to build and sell a plant its own former customers rejected on price — funding ≠ demand.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull case. The structural break in how WWR "makes money": it doesn't, and the path to doing so just lost both its demand anchor and its policy subsidy in the same quarter. Revenue concentration is infinite — 100% of intended CSPG revenue was two customers, now zero. The moat (non-HF IP) is irrelevant to a plant that can't be financed. The most dangerous competitor bulls underestimate is NOVONIX — same "domestic anode" pitch but with a $754.8M DOE loan and Panasonic/Stellantis/PowerCo offtakes already in hand; if Washington backs one domestic anode champion, the funded incumbent wins and WWR is redundant. Worst capital-allocation moves: floating-price convertibles and a permanent ATM that structurally transfer value from holders to note-holders and new buyers; larger RSU grants amid the drawdown. For today's ~$0.47 to hold, you must assume a government loan AND a new offtake both close before the cash/covenant clock and listing rules force a reverse split — a compound bet. If the (nonexistent) growth "disappoints by 20–30%," it's moot; the honest short scenario is abandonment/impairment of the $128M CIP, which is entirely plausible and would confirm the equity as a near-zero.

But the short is a trap, not a gift (this is why conviction is MEDIUM, not HIGH): WWR is a $0.47, ~$60M, heavily-retail, policy-headline micro-cap with a history of +300%+ single-year swings. A DOE/EXIM award, a re-filed tariff case, a DPA grant, or a strategic stake (à la Eni→NMG) could squeeze it 2–4× in a session. Borrow is likely tight/expensive and the tape is violent. The right expression is avoid / underweight / do-not-own, not a naked short.

Lens 14 · Fifteen Questions for Management (ordered by information value)

1. With both FCA and SK On terminated, do you have a single binding or near-binding CSPG offtake letter in hand today — and if not, what is the honest probability one closes in 2026?
2. EXIM: are you at a letter of interest or an actual application under review — and does EXIM's underwriting require a signed offtake you don't currently have? How do you break that Catch-22?
3. What is the precise cash figure and covenant date at which you must either raise, reverse-split, or halt — and what's the plan at that line?
4. The convertible notes convert at 92% of the 5-day-low VWAP. Why did you choose an instrument that dilutes faster as the stock falls, and will you commit to not issuing more floating-price paper?
5. Given the ITC's negative injury vote killed the anode tariff, what is your revised view on whether domestic CSPG can be price-competitive with Chinese anode without a tariff at recovered graphite prices?
6. Is the ~$115M Phase-I remaining still firm after tariff-driven equipment cost pressure, or is a further budget revision coming?
7. Under what scenario do you write down the $128M of construction-in-progress — and what is your current recoverability assumption?
8. Would you sell or JV Kellyton to a funded strategic (NOVONIX, a Korean/Japanese cell maker, an oil major like Eni) rather than dilute holders further to finish it alone?
9. What replacement customers are actually in qualification (not "discussions"), at what batch stage, and when could one convert to a contract?
10. Coosa's IA economics are 89% Inferred resource and the Indicated-only case isn't economic. What drill spend converts enough to Indicated to make Coosa a real feedstock decision, and is that spend justifiable now?
11. Insider ownership is modest and RSU grants grew in 2025. Will the board tie executive equity to financing-closed and first-production milestones rather than time-vesting?
12. What is the realistic first-CSPG-production date from today, stacking financing close + 12-month build + qualification?
13. If graphite prices stay 50–70% below the 2022 peak through 2027, does Phase I clear its cost of capital at all?
14. What is your contingency if NYSE American issues a low-price/continued-listing deficiency — timing and ratio of any reverse split?
15. What specifically have you learned about scaling from the qualification line (>1 mt) to 12,500 mt/yr, given no one on the team has produced graphite commercially?

---